BCLI Brainstorm Cell Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: BCLI

Price (delayed)

$3.10

Market cap

$110.74M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.07

Enterprise value

$80.12M

Sector: Healthcare
Industry: Biotechnology
Website: http://www.brainstorm-cell.com/

Highlights

The equity has grown by 37% from the previous quarter
The net income has decreased by 37% YoY and by 15% QoQ
BCLI's quick ratio is down by 20% QoQ

Key stats

What are the main financial stats of BCLI
Market
Shares outstanding
35.72M
Market cap
$110.74M
Enterprise value
$80.12M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.76
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$31.68M
EBITDA
-$31.47M
Free cash flow
-$35.57M
Per share
EPS
-$1.07
Free cash flow per share
-$1.19
Book value per share
$1.12
Revenue per share
$0
TBVPS
$1.72
Balance sheet
Total assets
$51.26M
Total liabilities
$15.8M
Debt
$7.22M
Equity
$35.46M
Working capital
$32.01M
Liquidity
Debt to equity
0.2
Current ratio
3.85
Quick ratio
3.76
Net debt/EBITDA
0.97
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-105%
Return on equity
-158.5%
Return on invested capital
-1,075.8%
Return on capital employed
-79.2%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BCLI stock price

How has the Brainstorm Cell Therapeutics stock price performed over time
Intraday
-0.96%
1 week
-11.68%
1 month
-25.66%
1 year
-48.93%
YTD
-31.57%
QTD
-19.06%

Financial performance

How have Brainstorm Cell Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$31.68M
Net income
-$31.81M
Gross margin
N/A
Net margin
N/A
Brainstorm Cell Therapeutics's operating income has decreased by 38% YoY and by 14% QoQ
The net income has decreased by 37% YoY and by 15% QoQ

Growth

What is Brainstorm Cell Therapeutics's growth rate over time

Valuation

What is Brainstorm Cell Therapeutics stock price valuation
P/E
N/A
P/B
2.76
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
BCLI's price to book (P/B) is 90% less than its 5-year quarterly average of 28.3 and 84% less than its last 4 quarters average of 17.9
The equity has grown by 37% from the previous quarter

Efficiency

How efficient is Brainstorm Cell Therapeutics business performance
The return on assets has surged by 60% year-on-year and by 27% since the previous quarter
The company's return on equity has surged by 53% QoQ

Dividends

What is BCLI's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BCLI.

Financial health

How did Brainstorm Cell Therapeutics financials performed over time
Brainstorm Cell Therapeutics's total liabilities has soared by 135% from the previous quarter but it has decreased by 16% YoY
Brainstorm Cell Therapeutics's total assets has soared by 57% from the previous quarter
BCLI's debt is 80% less than its equity
The equity has grown by 37% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.